A Rough Close to the Week for Biotech Stocks
Insights - To say that Biogen (BIIB) disappointed in a big way on Friday would be an understatement. With its second quarter earnings release on Friday morning … Continue Reading
Read NowRecap
It’s Been a Yawner of a Summer
Insights - The prettiest girl at the ball, Receptos (RCPT), went home with a handsome suitor this week. Celgene (CELG) is paying $7.2 billion, or $232 per … Continue Reading
Read Now
Yet Again, This Weekend May Be More Important Than This Week
Insights - Yet another choppy week for investors, and we’re going into another weekend in which decisions overseas will impact U.S. markets first thing on Monday. Greece submitted … Continue Reading
Read NowPoop Pills Worth $2 Billion in Latest Biotech IPO. Yep, Poop Pills
Insights - That’s a bit disingenuous, but Seres Health’s (MCRB) SER-109 isn’t far from it. The company made a splash on Friday when it IPO’d at $18, and … Continue Reading
Read NowBiotech Stocks Surged Through a Key Level this Week
Insights - Disparate results from two gene therapy developers are worth a mention in this week’s biotech recap. Avalanche Biotechnologies (AAVL) blew up spectacularly this Monday with … Continue Reading
Read NowA Roundup of Last Week in Healthcare
Recap - If you were hiding under a rock this week, three events stood out in the world of biotech investing. On Tuesday and Wednesday, a panel … Continue Reading
Read NowBiotech Ended on a High Note this Week
Recap - Biotech has been in a funk for over a week now, though Friday finished strong. iShares’ NASDAQ Biotechnology ETF (IBB) has been stuck hovering just … Continue Reading
Read Now